| # | Pathway | Proteins |
|---|
| 1 | ECM-receptor interaction | ENSAPLP00000000463, ENSAPLP00000014466, ENSAPLP00000009107, ENSAPLP00000013858, ENSAPLP00000013787, ENSAPLP00000000534, ENSAPLP00000012559, ENSAPLP00000016096 |
| 2 | Protein digestion and absorption | ENSAPLP00000000463, ENSAPLP00000008210, ENSAPLP00000012993, ENSAPLP00000012763, ENSAPLP00000016096 |
| 3 | Hypertrophic cardiomyopathy (HCM) | ENSAPLP00000009107, ENSAPLP00000004152, ENSAPLP00000002674, ENSAPLP00000003219, ENSAPLP00000016219, ENSAPLP00000009880 |
| 4 | Dilated cardiomyopathy | ENSAPLP00000009107, ENSAPLP00000004152, ENSAPLP00000002674, ENSAPLP00000003219, ENSAPLP00000016219, ENSAPLP00000009880 |
| 5 | Focal adhesion | ENSAPLP00000000463, ENSAPLP00000014466, ENSAPLP00000010282, ENSAPLP00000009107, ENSAPLP00000013858, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000012559, ENSAPLP00000016096, ENSAPLP00000009880 |
| 6 | PI3K-Akt signaling pathway | ENSAPLP00000000463, ENSAPLP00000014466, ENSAPLP00000009107, ENSAPLP00000013858, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000012559, ENSAPLP00000014548, ENSAPLP00000016096 |
| 7 | Viral myocarditis | ENSAPLP00000004152, ENSAPLP00000003050, ENSAPLP00000016219, ENSAPLP00000009880 |
| 8 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ENSAPLP00000009107, ENSAPLP00000004152, ENSAPLP00000002674, ENSAPLP00000016219, ENSAPLP00000009880 |
| 9 | Platelet activation | ENSAPLP00000004094, ENSAPLP00000010282, ENSAPLP00000009107, ENSAPLP00000004030, ENSAPLP00000003867, ENSAPLP00000009880 |
| 10 | Tight junction | ENSAPLP00000014910, ENSAPLP00000010282, ENSAPLP00000007261, ENSAPLP00000007172, ENSAPLP00000005955, ENSAPLP00000009880 |
| 11 | Synthesis and degradation of ketone bodies | ENSAPLP00000014420, ENSAPLP00000010177 |
| 12 | Regulation of actin cytoskeleton | ENSAPLP00000009727, ENSAPLP00000010282, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000012559, ENSAPLP00000005955, ENSAPLP00000004998, ENSAPLP00000009880 |
| 13 | Ribosome | ENSAPLP00000012634, ENSAPLP00000007620, ENSAPLP00000015662, ENSAPLP00000016333, ENSAPLP00000015078, ENSAPLP00000010726, ENSAPLP00000008154 |
| 14 | Salmonella infection | ENSAPLP00000009727, ENSAPLP00000003050, ENSAPLP00000005955, ENSAPLP00000009880 |
| 15 | Phenylalanine metabolism | ENSAPLP00000005038, ENSAPLP00000004066 |
| 16 | Shigellosis | ENSAPLP00000009727, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000009880 |
| 17 | Bacterial invasion of epithelial cells | ENSAPLP00000005099, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000012559, ENSAPLP00000009880 |
| 18 | Proteoglycans in cancer | ENSAPLP00000009107, ENSAPLP00000013972, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000012559, ENSAPLP00000013792, ENSAPLP00000009880 |
| 19 | Leukocyte transendothelial migration | ENSAPLP00000010282, ENSAPLP00000009107, ENSAPLP00000013972, ENSAPLP00000003050, ENSAPLP00000009880 |
| 20 | Complement and coagulation cascades | ENSAPLP00000004094, ENSAPLP00000004030, ENSAPLP00000003867, ENSAPLP00000003063 |
| 21 | Malaria | ENSAPLP00000005443, ENSAPLP00000011743 |
| 22 | Pathogenic Escherichia coli infection | ENSAPLP00000009107, ENSAPLP00000008717, ENSAPLP00000009880, ENSAPLP00000007755 |
| 23 | African trypanosomiasis | ENSAPLP00000013858, ENSAPLP00000005443 |
| 24 | Butanoate metabolism | ENSAPLP00000014420, ENSAPLP00000010177 |
| 25 | Small cell lung cancer | ENSAPLP00000009107, ENSAPLP00000013858, ENSAPLP00000012559 |
| 26 | Tyrosine metabolism | ENSAPLP00000005038, ENSAPLP00000004066 |
| 27 | beta-Alanine metabolism | ENSAPLP00000014321, ENSAPLP00000004066 |
| 28 | Staphylococcus aureus infection | ENSAPLP00000004094, ENSAPLP00000008717 |
| 29 | Estrogen signaling pathway | ENSAPLP00000000447, ENSAPLP00000013972, ENSAPLP00000014548 |
| 30 | Legionellosis | ENSAPLP00000000447, ENSAPLP00000004358 |
| 31 | Valine, leucine and isoleucine degradation | ENSAPLP00000014321, ENSAPLP00000014420, ENSAPLP00000010177 |
| 32 | Amyotrophic lateral sclerosis (ALS) | ENSAPLP00000003050, ENSAPLP00000012498 |
| 33 | Vascular smooth muscle contraction | ENSAPLP00000005955, ENSAPLP00000015007, ENSAPLP00000002381 |
| 34 | Toxoplasmosis | ENSAPLP00000000447, ENSAPLP00000009107, ENSAPLP00000013858 |
| 35 | Endocrine and other factor-regulated calcium reabsorption | ENSAPLP00000005099, ENSAPLP00000006303 |
| 36 | Adherens junction | ENSAPLP00000003052, ENSAPLP00000003050, ENSAPLP00000009880 |
| 37 | Sphingolipid metabolism | ENSAPLP00000007794 |
| 38 | Type I diabetes mellitus | ENSAPLP00000004358 |
| 39 | Influenza A | ENSAPLP00000003661, ENSAPLP00000000447, ENSAPLP00000009880 |
| 40 | Axon guidance | ENSAPLP00000009975, ENSAPLP00000009107, ENSAPLP00000003050 |
| 41 | Rap1 signaling pathway | ENSAPLP00000009727, ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000009880 |
| 42 | Thyroid hormone synthesis | ENSAPLP00000002711, ENSAPLP00000014548 |
| 43 | Propanoate metabolism | ENSAPLP00000014321, ENSAPLP00000014420 |
| 44 | Lysosome | ENSAPLP00000014136, ENSAPLP00000005099, ENSAPLP00000007794, ENSAPLP00000014590 |
| 45 | Ribosome biogenesis in eukaryotes | ENSAPLP00000013416, ENSAPLP00000006775 |
| 46 | Phagosome | ENSAPLP00000009107, ENSAPLP00000003050, ENSAPLP00000009880, ENSAPLP00000007755 |
| 47 | Synaptic vesicle cycle | ENSAPLP00000005099, ENSAPLP00000006303 |
| 48 | Cardiac muscle contraction | ENSAPLP00000002674, ENSAPLP00000003219 |
| 49 | Antigen processing and presentation | ENSAPLP00000000447, ENSAPLP00000002711 |
| 50 | Protein export | ENSAPLP00000002711 |
| 51 | Prion diseases | ENSAPLP00000000447, ENSAPLP00000002711 |
| 52 | Protein processing in endoplasmic reticulum | ENSAPLP00000000447, ENSAPLP00000002711, ENSAPLP00000011000, ENSAPLP00000014548 |
| 53 | Terpenoid backbone biosynthesis | ENSAPLP00000014420 |
| 54 | Phototransduction - fly | ENSAPLP00000009880 |
| 55 | Amoebiasis | ENSAPLP00000012216, ENSAPLP00000013858, ENSAPLP00000012559 |
| 56 | RNA degradation | ENSAPLP00000014331, ENSAPLP00000004358 |
| 57 | Histidine metabolism | ENSAPLP00000003438 |
| 58 | Renin-angiotensin system | ENSAPLP00000012763 |
| 59 | MicroRNAs in cancer | ENSAPLP00000014466, ENSAPLP00000013972, ENSAPLP00000003219 |
| 60 | Pathways in cancer | ENSAPLP00000009107, ENSAPLP00000013972, ENSAPLP00000013858, ENSAPLP00000003050, ENSAPLP00000012559, ENSAPLP00000014548 |
| 61 | Bladder cancer | ENSAPLP00000013972 |
| 62 | Fat digestion and absorption (no map in kegg database) | ENSAPLP00000014420 |
| 63 | Sphingolipid signaling pathway | ENSAPLP00000007794, ENSAPLP00000003050 |
| 64 | Porphyrin and chlorophyll metabolism | ENSAPLP00000007495 |
| 65 | NOD-like receptor signaling pathway | ENSAPLP00000014548 |
| 66 | Inositol phosphate metabolism | ENSAPLP00000014321 |
| 67 | Mineral absorption | ENSAPLP00000015679 |
| 68 | Systemic lupus erythematosus | ENSAPLP00000001729, ENSAPLP00000001720 |
| 69 | MAPK signaling pathway | ENSAPLP00000000447, ENSAPLP00000003050, ENSAPLP00000002674 |
| 70 | Fc gamma R-mediated phagocytosis | ENSAPLP00000003050, ENSAPLP00000004998 |
| 71 | HIF-1 signaling pathway | ENSAPLP00000015679, ENSAPLP00000003760 |
| 72 | Fructose and mannose metabolism | ENSAPLP00000003760 |
| 73 | Leishmaniasis | ENSAPLP00000009107 |
| 74 | Glycine, serine and threonine metabolism | ENSAPLP00000004066 |
| 75 | Colorectal cancer | ENSAPLP00000003050 |
| 76 | Alcoholism | ENSAPLP00000001729, ENSAPLP00000001720 |
| 77 | Tryptophan metabolism | ENSAPLP00000014420 |
| 78 | Pancreatic cancer | ENSAPLP00000003050 |
| 79 | Viral carcinogenesis | ENSAPLP00000003050, ENSAPLP00000001720, ENSAPLP00000004998 |
| 80 | Adrenergic signaling in cardiomyocytes | ENSAPLP00000002674, ENSAPLP00000003219 |
| 81 | VEGF signaling pathway | ENSAPLP00000003050 |
| 82 | Toll-like receptor signaling pathway | ENSAPLP00000003050 |
| 83 | Lysine degradation | ENSAPLP00000014420 |
| 84 | Vasopressin-regulated water reabsorption | ENSAPLP00000010780 |
| 85 | Oxytocin signaling pathway | ENSAPLP00000002674, ENSAPLP00000009880 |
| 86 | Pertussis | ENSAPLP00000009107 |
| 87 | B cell receptor signaling pathway | ENSAPLP00000003050 |
| 88 | Pancreatic secretion | ENSAPLP00000003050 |
| 89 | Transcriptional misregulation in cancer | ENSAPLP00000013972 |
| 90 | TNF signaling pathway | ENSAPLP00000013972 |
| 91 | Pentose phosphate pathway | ENSAPLP00000003760 |
| 92 | Choline metabolism in cancer | ENSAPLP00000003050 |
| 93 | Spliceosome | ENSAPLP00000003661, ENSAPLP00000000447, ENSAPLP00000014331 |
| 94 | Natural killer cell mediated cytotoxicity | ENSAPLP00000003050 |
| 95 | Renal cell carcinoma | ENSAPLP00000003050 |
| 96 | Fc epsilon RI signaling pathway | ENSAPLP00000003050 |
| 97 | Vibrio cholerae infection | ENSAPLP00000009880 |
| 98 | Prostate cancer | ENSAPLP00000014548 |
| 99 | Glyoxylate and dicarboxylate metabolism | ENSAPLP00000014420 |
| 100 | Measles | ENSAPLP00000000447 |
| 101 | Carbon metabolism (no map in kegg database) | ENSAPLP00000014321, ENSAPLP00000003760, ENSAPLP00000014420 |
| 102 | PPAR signaling pathway | ENSAPLP00000003052 |
| 103 | Gastric acid secretion (no map in kegg database) | ENSAPLP00000009880 |
| 104 | Epithelial cell signaling in Helicobacter pylori infection | ENSAPLP00000003050 |
| 105 | Fatty acid metabolism (no map in kegg database) | ENSAPLP00000014420 |
| 106 | Osteoclast differentiation | ENSAPLP00000003050 |
| 107 | Pyruvate metabolism | ENSAPLP00000014420 |
| 108 | Hippo signaling pathway - fly | ENSAPLP00000009880 |
| 109 | Fatty acid degradation | ENSAPLP00000014420 |
| 110 | Cell adhesion molecules (CAMs) | ENSAPLP00000009107 |
| 111 | Endocytosis | ENSAPLP00000000447, ENSAPLP00000005099, ENSAPLP00000006303, ENSAPLP00000010780 |
| 112 | Gap junction | ENSAPLP00000007755 |
| 113 | AMPK signaling pathway | ENSAPLP00000010780 |
| 114 | Thyroid hormone signaling pathway | ENSAPLP00000009880 |
| 115 | Glycolysis / Gluconeogenesis | ENSAPLP00000003760 |
| 116 | Wnt signaling pathway | ENSAPLP00000003050 |
| 117 | Hepatitis B | ENSAPLP00000013972 |
| 118 | cAMP signaling pathway | ENSAPLP00000003050 |
| 119 | Hippo signaling pathway | ENSAPLP00000009880 |
| 120 | Neurotrophin signaling pathway | ENSAPLP00000003050 |
| 121 | Epstein-Barr virus infection | ENSAPLP00000013416, ENSAPLP00000000447 |
| 122 | Tuberculosis | ENSAPLP00000004358 |
| 123 | Biosynthesis of amino acids (no map in kegg database) | ENSAPLP00000003760 |
| 124 | Insulin signaling pathway | ENSAPLP00000003052 |
| 125 | Ras signaling pathway | ENSAPLP00000003050 |
| 126 | Non-alcoholic fatty liver disease (NAFLD) | ENSAPLP00000003050 |
| 127 | Huntington's disease | ENSAPLP00000005099, ENSAPLP00000006303 |
| 128 | Chemokine signaling pathway | ENSAPLP00000003050 |
| 129 | HTLV-I infection | ENSAPLP00000013416 |
| 130 | Parkinson's disease | ENSAPLP00000010540 |
| 131 | Alzheimer's disease | ENSAPLP00000011743 |
| 132 | RNA transport | ENSAPLP00000013416 |
| 133 | Metabolic pathways (no map in kegg database) | ENSAPLP00000007794, ENSAPLP00000014321, ENSAPLP00000003760, ENSAPLP00000004066, ENSAPLP00000014420 |